MIRM Mirum Pharmaceuticals, Inc.: Business Value to Revenue

Official company branding of Mirum (MIRM)

Mirum Pharmaceuticals generates revenue based on the sale of its patented drug LIVMARLI for children. Business valuation via EV/Sales confirms current market dynamics, where this metric equals 9846.69. Expanding its presence in Asia and Europe through distributors, combined with aggressive portfolio scaling and the pursuit of new medical indications, should ensure long-term capitalization growth for the company.

MIRM Mirum Pharmaceuticals Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

MIRM (Mirum): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental company valuation:Mirum Pharmaceuticals MIRM
Product sample of mirumpharma.com

This indicator compares the total enterprise value to sales volume, excluding the impact of debt load to determine the actual market value of one dollar of revenue. For Mirum Pharmaceuticals (MIRM), which focuses on a narrow segment of orphan liver diseases, the EV/Sales ratio reflects the efficiency of monetizing its developments, allowing the chart's price action to assess capital stability and the operational model's margin of safety.